...
首页> 外文期刊>Prescrire international >Caplaelzumab (cablivp) and acquired thrombotlc thrombocytopenic purpura In adolescents
【24h】

Caplaelzumab (cablivp) and acquired thrombotlc thrombocytopenic purpura In adolescents

机译:Caplaelzumab (cablivp) and acquired thrombotlc thrombocytopenic purpura In adolescents

获取原文
获取原文并翻译 | 示例
           

摘要

Acquired thrombotic thrombocyto-penic purpura is a rare disease, which is almost always fatal within a few days, in the absence of treatment. It is characterised by a combination of wide-ranging organ damage due to multiple thromboses, thrombo-cytopenia related to aggregation of platelets within thrombi, and haemolytic anaemia. The condition is linked to an increase in levels of von Willebrand factor, a procoagulant protein (1,2). Treatment of an episode is based on plasma exchange, usually for several days. Relapses are frequent, often after a relatively short interval, but they sometimes occur after several years (1).

著录项

  • 来源
    《Prescrire international》 |2022年第243期|295-295|共1页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类 药学;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号